Results 121 to 130 of about 8,252,790 (324)

FDA New Drug Approval Times, Prescription Drug User Fees, and R & D Spending [PDF]

open access: yes
FDA-approval times have declined significantly since the enactment of the Prescription Drug User Fee Act (PDUFA) in 1992. As a result, present value expected returns to pharmaceutical R&D have likely increased.
Golec, Joseph H.   +3 more
core  

Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada

open access: yesCurrent Oncology
Medical oncology is a rapidly evolving field, with new medications being discovered yearly, contributing to increased survival rates. However, accessing drugs in a timely manner can be challenging. In Quebec, Canada, a physician can prescribe an unlisted
Adam Miller   +4 more
doaj   +1 more source

Smaller is better: nanobodies meet NMR

open access: yesFEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Comparison of the conditional approvals for anticancer drugs supported by single-arm trials in China and the United States: clinical evidence, post-marketing requirements, and regulatory outcomes

open access: yesFrontiers in Pharmacology
PurposeDescribe and compare the clinical evidence, post-marketing requirements, and regulatory outcomes of all anticancer drugs that have obtained conditional or accelerated approval based on single-arm trial data in China and the United States ...
Yang Du, Shuo Zhang, Li Yang
doaj   +1 more source

Neutralization of the PTX3/CD44 axis suppresses TGF‐β1 signaling in kidney fibrosis

open access: yesFEBS Letters, EarlyView.
This study investigates how the PTX3/CD44 axis promotes kidney fibrosis by activating TGF‐β1 signaling. We demonstrate that the neutralizing antibody WHC‐001 effectively inhibits this pathway, suppressing myofibroblast activation and partial epithelial–mesenchymal transition (EMT).
Chao‐Chun Cheng   +8 more
wiley   +1 more source

Is drug development in India is responsive to disease burden: A descriptive study

open access: yesPerspectives in Clinical Research
Objective: The aim of this study was to investigate the association between approved drugs and disease burden in India and to assess the need to address the unmet healthcare needs of the public. Materials and Methods: This descriptive study was conducted
Divya Goel, Arnav Gupta
doaj   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Drug Approval Process in the United States

open access: yes, 2018
The drug approval process in any country involves a balancing of conflicting social objectives: safety and access. Faster approval leads to quicker access to potentially life-saving medicine, yet could also lead to false positives or, worse, unsafe ...
Z. John Lu, Stuart O. Schweitzer
core   +1 more source

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

open access: yesSignal Transduction and Targeted Therapy
The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering ...
Wenjing Xiao   +7 more
semanticscholar   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

open access: yesFEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy